- Organizations: Clearside Biomedical
Pipeline
Clearside Biomedical reports phase 3 plans for SCS wet AMD therapy
Announcement follows company’s end-of-phase 2 meeting with FDA to discuss next steps for CLS-AX (axitinib injectable suspension).
Pipeline
Clearside Biomedical reports phase 2b analyses of CLS-AX for wet AMD
Data from two sub-groups to determine design of two phase 3 clinical trials evaluating the use of axitinb injectable suspension with the SCS Microinjector.Pipeline
Clearside Biomedical reports positive topline phase 2b data on CLX-AX for wet AMD
A reduced treatment burden was noted in 84% of participants over 6 months, demonstrating the TKI’s prolonged duration and targeted delivery.
Research
New consensus guidelines published for suprachoroidal space injections
Five key recommendations by a panel of 15 retinal physicians are based on published clinical evidence and experience.
Business
Clearside Biomedical names retinal industry veteran as CMO
Victor Chong, MD, MBA, assumed his new role on March 14.
Pipeline
Enrollment opens for Clearside Biomedical's ODYSSEY phase 2b trial for wet AMD
CLS-AX is being assessed for suprachoroidal delivery using the company’s proprietary CSC Microinjector.
Pipeline
Clearside Biomedical releases plans for wet AMD ODYSSEY trial
Phase 2b trial on CLS-AX follows positive 6-month data from OASIS phase 1/2a extension study.
Pipeline